EUCTR2014-004932-20-PL进行中（未招募）1 期
A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066/ABBV-066 (risankizumab) as add-on therapy over 24 weeks in patients with severe persistent asthma.
Boehringer Ingelheim RCV GmbH & CoKG0 个研究点目标入组 200 人开始时间: 2015年8月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Pre-bronchodilator clinic measured FEV1 between 40% and 85% of predicted normal.
- •2. One year history of asthma diagnosed by a physician, and have FEV1 reversibility of 12% and an absolute change of at least 200 mL after administration of 400 µg salbutamol.
- •3. Must be on at least medium dose inhaled corticosteroids and at least one other asthma controller medication for at least one year.
- •4. Must have documented history of two or more severe asthma exacerbations in the last 12 months or severe asthma exacerbation in the last 12 months with hospitalization or one exacerbation in the last 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Patients with a significant disease other than asthma.
- •2. Patients who are not able to produce sputum or sputum samples of sufficient quality.
- •3. Patients who had clinically relevant history of intubation for asthma exacerbation in the past year.
- •4. Patients diagnosed with any concurrent respiratory disease.
- •5. Recent history (within 6 months) of myocardial infarction or hospitalized for cardiac failure in the past year.
- •6. Patients who have undergone thoracotomy with pulmonary resection.
- •7. Patients who have undergone bronchial thermoplasty or radiotherapy procedure in the past year or have planned procedures during the study.
- •8. Patients taking oral corticosteroids with a total daily dose of more than 20 mg prednisone (or equivalent) in the past 6 weeks.
- •9. Pregnant or nursing women.
- •10. Women of childbearing potential that, if sexually active, is unwilling to use a highly effective method of birth control.
- •11. Clinically relevant acute infections or chronic infections.
- •12. Have received any live bacterial or live viral vaccination in the last12 weeks.
- •13. Have received Bacille Calmette-Guerin (BCG) vaccination in the last 12 months.
- •14. Have received treatment with ustekinumab (Stelara®).
- •15. Have received treatment with any other biologics in the last 3 months or within 6 times the half-life of the compound.
- •16. History of allergy or hypersensitivity to biologic agents or its
- •excipients, or hypersensitivity to beta-adrenergic medications.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of BI 655066 in patients with severe persistent asthmaEUCTR2014-004932-20-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.369
进行中（未招募）
1 期
Efficacy and safety of BI 655066 (risankizumab) in patients with severe persistent asthma.EUCTR2014-004932-20-GBBoehringer Ingelheim Limited200
进行中（未招募）
不适用
Efficacy and safety of BI 655066 in patients with severe persistent asthma.Severe AsthmaEUCTR2014-004932-20-HUBoehringer Ingelheim RCV GmbH & CoKG450
已完成
2 期
A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 weeks in patients with severe persistent asthma.Severe asthma10038716NL-OMON45129Boehringer Ingelheim3
进行中（未招募）
1 期
Efficacy and safety of BI 655066 (risankizumab) in patients with severe persistent asthma.EUCTR2014-004932-20-BESCS Boehringer Ingelheim Comm.V200